اسکلروستین
برای مطالعهٔ بیشتر

Balemans W, Van Hul W (2007). "Human genetics of SOST". Journal of Musculoskeletal & Neuronal Interactions. 6 (4): 355–6. PMID 17185822.
Balemans W, Patel N, Ebeling M, Van Hul E, Wuyts W, Lacza C, Dioszegi M, Dikkers FG, Hildering P, Willems PJ, Verheij JB, Lindpaintner K, Vickery B, Foernzler D, Van Hul W (Feb 2002). "Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease". Journal of Medical Genetics. 39 (2): 91–7. doi:10.1136/jmg.39.2.91. PMC 1735035. PMID 11836356.
Staehling-Hampton K, Proll S, Paeper BW, Zhao L, Charmley P, Brown A, Gardner JC, Galas D, Schatzman RC, Beighton P, Papapoulos S, Hamersma H, Brunkow ME (Jun 2002). "A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population". American Journal of Medical Genetics. 110 (2): 144–52. doi:10.1002/ajmg.10401. PMID 12116252.
Balemans W, Foernzler D, Parsons C, Ebeling M, Thompson A, Reid DM, Lindpaintner K, Ralston SH, Van Hul W (Oct 2002). "Lack of association between the SOST gene and bone mineral density in perimenopausal women: analysis of five polymorphisms". Bone. 31 (4): 515–9. doi:10.1016/S8756-3282(02)00844-X. PMID 12398949.
Clark HF, Gurney AL, Abaya E, Baker K, Baldwin D, Brush J, Chen J, Chow B, Chui C, Crowley C, Currell B, Deuel B, Dowd P, Eaton D, Foster J, Grimaldi C, Gu Q, Hass PE, Heldens S, Huang A, Kim HS, Klimowski L, Jin Y, Johnson S, Lee J, Lewis L, Liao D, Mark M, Robbie E, Sanchez C, Schoenfeld J, Seshagiri S, Simmons L, Singh J, Smith V, Stinson J, Vagts A, Vandlen R, Watanabe C, Wieand D, Woods K, Xie MH, Yansura D, Yi S, Yu G, Yuan J, Zhang M, Zhang Z, Goddard A, Wood WI, Godowski P, Gray A (Oct 2003). "The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment". Genome Research. 13 (10): 2265–70. doi:10.1101/gr.1293003. PMC 403697. PMID 12975309.
Sevetson B, Taylor S, Pan Y (Apr 2004). "Cbfa1/RUNX2 directs specific expression of the sclerosteosis gene (SOST)". The Journal of Biological Chemistry. 279 (14): 13849–58. doi:10.1074/jbc.M306249200. PMID 14739291.
van Bezooijen RL, Roelen BA, Visser A, van der Wee-Pals L, de Wilt E, Karperien M, Hamersma H, Papapoulos SE, ten Dijke P, Löwik CW (Mar 2004). "Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist". The Journal of Experimental Medicine. 199 (6): 805–14. doi:10.1084/jem.20031454. PMC 2212719. PMID 15024046.
Winkler DG, Yu C, Geoghegan JC, Ojala EW, Skonier JE, Shpektor D, Sutherland MK, Latham JA (Aug 2004). "Noggin and sclerostin bone morphogenetic protein antagonists form a mutually inhibitory complex". The Journal of Biological Chemistry. 279 (35): 36293–8. doi:10.1074/jbc.M400521200. PMID 15199066.
Zhang Z, Henzel WJ (Oct 2004). "Signal peptide prediction based on analysis of experimentally verified cleavage sites". Protein Science. 13 (10): 2819–24. doi:10.1110/ps.04682504. PMC 2286551. PMID 15340161.
Sutherland MK, Geoghegan JC, Yu C, Turcott E, Skonier JE, Winkler DG, Latham JA (Oct 2004). "Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation". Bone. 35 (4): 828–35. doi:10.1016/j.bone.2004.05.023. PMID 15454089.
Uitterlinden AG, Arp PP, Paeper BW, Charmley P, Proll S, Rivadeneira F, Fang Y, van Meurs JB, Britschgi TB, Latham JA, Schatzman RC, Pols HA, Brunkow ME (Dec 2004). "Polymorphisms in the sclerosteosis/van Buchem disease gene (SOST) region are associated with bone-mineral density in elderly whites". American Journal of Human Genetics. 75 (6): 1032–45. doi:10.1086/426458. PMC 1182139. PMID 15514891.
Winkler DG, Sutherland MS, Ojala E, Turcott E, Geoghegan JC, Shpektor D, Skonier JE, Yu C, Latham JA (Jan 2005). "Sclerostin inhibition of Wnt-3a-induced C3H10T1/2 cell differentiation is indirect and mediated by bone morphogenetic proteins". The Journal of Biological Chemistry. 280 (4): 2498–502. doi:10.1074/jbc.M400524200. PMID 15545262.
Poole KE, van Bezooijen RL, Loveridge N, Hamersma H, Papapoulos SE, Löwik CW, Reeve J (Nov 2005). "Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation". FASEB Journal. 19 (13): 1842–4. doi:10.1096/fj.05-4221fje. PMID 16123173.
Gardner JC, van Bezooijen RL, Mervis B, Hamdy NA, Löwik CW, Hamersma H, Beighton P, Papapoulos SE (Dec 2005). "Bone mineral density in sclerosteosis; affected individuals and gene carriers". The Journal of Clinical Endocrinology and Metabolism. 90 (12): 6392–5. doi:10.1210/jc.2005-1235. PMID 16189254.
| ن ب وداروهای درمان بیماری‌های استخوان (M05) | ن ب وداروهای درمان بیماری‌های استخوان (M05) |
| --- | --- |
بیس فسفونات‌ها:  نیتروژنی آلندرونیت  ایباندرونیک اسید  Incadronic acid  اسید نریدرونیک  پامیدرونات  Risedronic acid  زولدرونیک اسید  غیر-نیتروژنی اسید اتیدرونیک  Clodronic acid  Tiludronic acid 
BMPها:  دیبوترمین آلفا  پروتئین ۷ ریخت‌زایی استخوان 
سایر:  بازدارندگان بازجذب Ipriflavone  Aluminium chlorohydrate  عامل استخوانی با عملکر دوگانه استرانسیوم رانلات  بازدارنده RANKL Denosumab  بازدارنده اسکلروستین Romosozumab  بازدارنده Cathepsin K Odanacatib  پروتئین مرتبط با هورمون پاراتیروئیدی آنالوگ‌های ساختاری Abaloparatide  تری‌پاراتاید  کلسی‌تونین  کلسیم  ویتامین دی